1
TITLE: Efficacy and safety of ixazomib plus lenalidomidedexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.
AUTHORS: Paul G Richardson; Herve Avet Loiseau; Antonio Palumbo; Luisa Viterbo; Arnon Nagler; Peter Ganly; Dina Ben Yehuda; Jesus San Miguel; Vincent V Rajkumar; Ludek Pour; Christian Langer; Nizar J Bahlis; Andrzej Pluta; Tamas Masszi; Deborah Berg; Jianchang C Lin; Helgi Van De Velde; Dixie Lee Esseltine; Alessandra di Baccot; Philippe Moreau;
PUBLISHED: 2016, SOURCE: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 34, ISSUE: 15
INDEXED IN: WOS
2
TITLE: Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib-Rituximab Versus Rituximab
AUTHORS: Bertrand Coiffier; Weimin M Li; Erin D Henitz; Jayaprakash D Karkera; Reyna Favis; Dana Gaffney; Alice Shapiro; Panteli Theocharous; Yusri A Elsayed; Helgi van de Velde; Michael E Schaffer; Evgenii A Osmanov; Xiaonan N Hong; Adriana Scheliga; Jiri Mayer; Fritz Offner; Simon Rule; Adriana Teixeira; Joanna Romejko Jarosinska; Sven de Vos; Michael Crump; Ofer Shpilberg; Pier Luigi Zinzani; Andrew Cakana; Dixie Lee Esseltine; George Mulligan; Deborah Ricci; ...More
PUBLISHED: 2013, SOURCE: CLINICAL CANCER RESEARCH, VOLUME: 19, ISSUE: 9
INDEXED IN: Scopus WOS CrossRef